Tumor Mutational Status May Predict Recurrence

Tumor Mutational Status May Predict Recurrence, Survival Patterns ...

Results from a retrospective analysis study found that tumor mutational status can potentially predict recurrence and survival patterns for ...

Tumor Mutational Burden and Somatic Mutation Status to Predict ...

Co-assessment of TMB with inflammatory markers and genetic mutations may better predict disease outcomes. The goal of this study was to evaluate the potential ...

Tumor evolution metrics predict recurrence beyond 10 years in ...

Genetic and morphological (Gleason) diversity were independent predictors of recurrence (hazard ratio (HR) = 3.12 and 95% confidence interval ( ...

Tumor mutational burden and somatic mutation status to predict ...

The goal of this study was to evaluate the potential for TMB and somatic mutations in combination to predict the recurrence of disease in advanced melanoma.

High Tumor Mutational Burden May Predict Improved Response to ...

Tumor mutational burden (TMB) is an emerging biomarker utilized in some cancers as a predictive tool to determine benefit to immune checkpoint inhibitor ...

A recurrence‐predictive model based on eight genes and tumor ...

... tumor mutational burden/microsatellite instability status in Stage II/III colorectal cancer ... A genomic mutation signature predicts the ...

Multiple gene mutations may predict recurrence in malignant ...

NEW YORK — Patients with primary malignant melanoma are at a higher risk for tumor recurrence if they have mutations in two or more ...

Prognostic Impact of Tumor Size and BRAF Mutational Status in ...

Larger tumor size was an independent predictor of EFS, regardless of the presence of BRAF mutations, highlighting that tumor size supersedes ...

The role of the genomic mutation signature and tumor mutation ...

The relapse mutation signature (RMS) and chromatin remodeling mutation signature (CRMS) were explored to predict the risk of relapse in patients ...

Tumor Mutational Burden as a Predictor of Immunotherapy Response

In some tumor types, there is evidence that low TMB, not TMB-H, predicts benefit from immune checkpoint blockade. Very low TMB may identify patients with ...

Tumor Mutation Burden Predicts Relapse in Papillary Thyroid ...

Background: The risk factors of papillary thyroid carcinoma (PTC) recurrence are meaningful for patients and clinicians. Tumor mutation burden (TMB) has been a ...

High tumor mutation burden fails to predict immune checkpoint ...

High tumor mutation burden (TMB-H) has been proposed as a predictive biomarker for response to immune checkpoint blockade (ICB).

Circulating Tumor DNA Analyses as Markers of Recurrence Risk ...

Postchemotherapy ctDNA analysis may define a patient subset that remains at high risk of recurrence despite completing standard adjuvant ...

REVIEW Tumour mutational burden: an overview for pathologists

Tumour mutational burden (TMB) is a diagnostic biomarker that can stratify cancer patients for response to immune checkpoint inhibitor therapies.

RAS Mutations Predict Recurrence-Free Survival ... - Sage Journals

KRAS mutation status was associated with increased lung recurrence in stage II–III colorectal cancer (CRC). Yaeger et al. reported that lung, ...

The USP8 mutational status may predict long‐term remission in ...

The incidence of recurrence in a 10-year follow-up was significantly higher in patients with USP8 mutant tumours after the initial remission (58 ...

Analysis of Tumor Mutational Burden, Progression-Free Survival ...

... status may serve as a potential novel biomarker for radiation sensitivity. ... A genomic-pathologic annotated risk model to predict recurrence in ...

The role of EGFR mutations in predicting recurrence in early and ...

Overall our findings suggest that while EGFR mutation status does not affect overall recurrence or survival, metastatic vs local recurrence may ...

RAS mutation: site of disease and recurrence pattern in colorectal ...

As RAS mutation status may represent a direct measure of tumor biology and appears strongly linked to oncologic outcomes, it has been recently included in a ...

Tumor mutational burden predicts the efficacy of pembrolizumab ...

The prevalence of TMB ≥175 mutations/exome among tumor types represented by >10 participants ranged from 4.1% (ovarian cancer) to 56.6% (melanoma) (online ...